Research improves treatment for patients with statin-associated adverse effects

September 10th, 2010 - 12:49 pm

Dr. Stephen Kopecky of the Department of Cardiovascular Diseases at Mayo Clinic describes statin intolerance as a condition that can be hard to diagnose and for which more research is needed.

Statins are the most commonly used drugs in the world for the treatment of high cholesterol. Classic patient reactions to statins, however, include muscle aches, cramps and weakness. Reactions may occur within a few months or up to several years later.

To better care for these patients, Mayo Clinic established the Statin Intolerance Clinic to diagnose, risk stratify, and treat patients with statin-associated adverse effects. Related research focuses on drugs that may help patients who gave up on statins years ago and on genetic testing that will allow physicians to predict the drugs and dosages that may be most effective for each patient.

Learn more about the Mayo Clinic Statin Intolerance Clinic and Dr. Kopecky’s research.

Share
By Miriam Wuensch | Posted in Cardiovascular | Tagged , , , , | Comments (1)

Carotid ultrasound identifies high-risk subclinical atherosclerosis in adults with low Framingham risk scores

September 3rd, 2010 - 12:37 pm

Dr. Robert (Todd) Hurst discusses research conducted at Mayo Clinic in Arizona that suggests that measuring the amount of artery disease an individual has may allow physicians to make more informed recommendations to patients.

Researchers  investigated whether the Carotid Intima Media Thickness (CIMT) test, a simple, safe ultrasound test to measure artery disease in the main artery in the neck, would help them better identify individuals that may be at risk. The study was published in the August 2010 issue of the  Journal of American Society of Echocardiography.

ABSTRACT
Background
Worldwide, cardiovascular (CV) disease remains the most common cause of morbidity and mortality. Although effective in predicting CV risk in select populations, the Framingham risk score (FRS) fails to identify many young individuals who experience premature CV events. Accordingly, the aim of this study was to determine the prevalence of high-risk carotid intima-media thickness (CIMT) or plaque, a marker of atherosclerosis and predictor of CV events, in young asymptomatic individuals with low and intermediate FRS (<2% annualized event rate) using the carotid ultrasound protocol recommended by the American Society of Echocardiography and the Society of Vascular Medicine.

Methods
Individuals aged < or = 65 years not taking statins and without diabetes mellitus or histories of coronary artery disease underwent CIMT and plaque examination for primary prevention. Clinical variables including lipid values, family history of premature coronary artery disease, and FRS and subsequent pharmacotherapy recommendations were retrospectively collected for statistical analysis.

Results
Of 441 subjects (mean age, 49.7 + or – 7.9 years), 184 (42%; 95% confidence interval, 37.3%-46.5%) had high-risk carotid ultrasound findings (CIMT > or = 75th percentile adjusted for age, gender, and race or presence of plaque). Of those with the lowest FRS of < or =5% (n = 336) (mean age, 48.0 + or – 7.6 years; mean FRS, 2.5 + or – 1.5%), 127 (38%; 95% confidence interval, 32.6%-43.0%) had high-risk carotid ultrasound findings. For individuals with FRS < or = 5% and high-risk carotid ultrasound findings (n = 127; mean age, 47.3 + or – 8.1 years; mean FRS, 2.5 + or – 1.5%), lipid-lowering therapy was recommended by their treating physicians in 77 (61%).

Conclusions
Thirty-eight percent of asymptomatic young to middle-aged individuals with FRS < or = 5% have abnormal carotid ultrasound findings associated with increased risk for CV events. Pharmacologic therapy for CV prevention was recommended in the majority of these individuals. The lack of radiation exposure, relatively low cost, and ability to detect early-stage atherosclerosis suggest that carotid ultrasound for CIMT and plaque detection should continue to be explored as a primary tool for CV risk stratification in young to middle-aged adults with low FRS.

Authors
Mackram Eleid, M.D.; Steven Lester, M.D.; Troy Wiedenbeck, M.D.; Sharad Patel, M.D.; Christopher Appleton, M.D.; Matthew Nelson, M.D.; J. Humphries; Robert Hurst, M.D.

Share
By Miriam Wuensch | Posted in Cardiovascular | Tagged , , , , , , , , | Comments (1)

Association of Aβ42, Aβ40 and Aβ42/Aβ40 with cognitive impairment not demented (CIND) and dementia in persons of Mexican ancestry (SALSA study): Different for diabetics versus non-diabetics?

August 26th, 2010 - 12:58 pm

Dr. Neill Graff-Radford of the Department of Neurology at Mayo Clinic in Florida discusses a recent study that used potential biomarkers predicting cognitive impairment to study persons of Mexican ancestry, in whom the incidence of type 2 diabetes is high. Researchers found that a low Aβ42/Aβ40 ratio or low Aβ42 may indicate impending dementia in non-diabetic study group participants, but that finding did not hold true for the group as a whole.

 

ABSTRACT
Background
Plasma Aβ40 and Aβ42 are potential biomarkers predicting cognitive impairment and dementia. These biomarkers have not been studied in persons of Mexican ancestry in whom type 2 diabetes is high. We evaluated the association of plasma Aβ40 and Aβ42 levels as well as their ratio with risk of CIND and Dementia.

Methods
In a nested case-control study, we matched normal controls (n=403) to incident dementia/CIND cases (n=211) by age at diagnosis (+/- 2 years). We used those with a plasma sample before or at dementia/CIND diagnosis. Using sandwich ELISAs, we measured Aβ40 with antibodies BNT77/BA27 and Aβ42 using BNT77/BC-05. Il-6, LDL-C, insulin and glucose were obtained from fasting samples at diagnosis. Diabetes was defined using ADA standards. Diabetes was present in 42% of cases and 26% of controls (p<0.0001). Insulin sensitivity was calculated using the QUICKI formula. Conditional logistic regression models including age as a classification variable APOE4 and time between sample and diagnosis (model 1) were used to assess association of each Aβ measure (after log transformation) with risk of dementia/CIND. We explored interactions with diabetic status. Model 2 adjusted for diabetic status, insulin sensitivity, LDL and Il-6.

Results
One standard deviation (SD) increase in log Aβ40 was associated with increased risk of dementia/CIND (OR=1.69, 95% confidence interval: 1.07-2.67, model 1). Adjustment for additional covariates reduced the association (OR=1.22, 0.75 – 2.05, model 2). Neither Aβ42 nor the Aβ42/Aβ40 ratio was associated with dementia/CIND. Tests for interaction of Aβ42 and Aβ42/Aβ40 with diabetes at dementia/CIND diagnosis were significant, however, for both model 1 and model 2. Among non-diabetics, a one SD increase in log Aβ42 was associated with a lower risk of dementia/CIND (OR=0.79, 0. 61-1.01, p for interaction=0.02, model 2). Also among non-diabetics, a one SD increase in Aβ42/Aβ40 (log transformed) was associated with a lower risk (OR=0.75, 0.59-0.96, p for interaction=0.02, model 2) of dementia/CIND.

Conclusion
In non-diabetic persons of Mexican ancestry, as in many Caucasians studies, a low Aβ42/Aβ40 ratio or low Aβ42 may indicate impending dementia. This outcome was not found for the whole group including diabetics. These results may help explain some of the contradictory findings in the literature. Further studies are needed in diabetics.

Learn more about Dr. Graff-Radford’s research.

Authors
Neill Graff-Radford, M.D.; Julia Crook, Ph.D.; John Lucas, Ph.D.; Linda Younkin; Greg Nah; Steven Younkin, M.D., Ph.D., senior author; Mary Haan, senior author

Share
By Miriam Wuensch | Posted in Neurology | Tagged , , , , , | Leave a comment

Radical prostatectomy performed without incision

August 18th, 2010 - 10:56 am

Dr. Mitchell Humphreys discusses a new surgical procedure that uses natural orifices as access points for cancer treatment. Natural Orifice Transluminal Endoscopic Surgery (NOTES) was recently used to perform a radical prostatectomy at Mayo Clinic in Arizona. The patient’s prostate and cancer were successfully removed through his urethra.

ABSTRACT
Natural orifice translumenal endoscopic surgical radical prostatectomy: proof of concept

This abstract reflects preliminary work completed on cadavers.  It is not reflective the of actual surgery. The study was published in the April 2009 issue of the Journal of Endourology.

Background: Innovations in minimally invasive surgery have led to the proposal of incision-free natural orifice translumenal endoscopic surgery (NOTES). This manuscript describes the initial technique of natural orifice translumenal endoscopic surgical radical prostatectomy (NOTES-RP).

Methods: NOTES-RP was performed on four male cadavers in a surgical simulation laboratory setting. The 100 W holmium:yttrium-aluminum-garnet laser, 550 microm end-firing laser fiber, 26F resectoscope, 7F laser stabilizing catheter, and continuous irrigation were used to radically resect and deliver the prostate of each cadaver into the bladder. The neurovascular bundles were preserved bilaterally, as well as the dorsal venous complex, bladder neck, and external sphincter. The entire resection was performed with the laser, while a rigid offset 27F nephroscope was used to perform the vesicourethral anastomosis using a laparoscopic suture device and knot pusher in an interrupted fashion. The prostate tissue was removed endoscopically with a tissue morcellator. After the initial NOTES-RP, a pelvic exploration with biopsy of neurovascular bundles, bladder, and urethral margins was performed.

Results: NOTES-RP was successfully executed in the cadaveric model. Pathologic evaluation of tissue demonstrates complete removal of all prostate tissue with preservation of the neurovascular bundles bilaterally as well as the external urinary sphincter.

Conclusion: The present work demonstrates the feasibility of NOTES-RP in the cadaver model. While further testing and instrument modification are necessary before clinical application, this concept demonstrates the evolving nature of minimally invasive surgery and what could be possible for patients.

Share
By Miriam Wuensch | Posted in Cancer, Urology | Tagged , , , , , | Comments (1)

Coronary artery disease management update

August 11th, 2010 - 9:18 am

Charanjit Rihal, M.D., chair of the Mayo Clinic Division of Cardiovascular Diseases, discusses advancements in the early detection and treatment of coronary artery disease, including medical therapy and revascularization in the form of percutaneous coronary intervention and bypass surgery. Dr. Rihal also discusses a continuing medical education course, Coronary Artery Disease: Prevention, Detection and Treatment, offered October 22-24, 2010, in Las Vegas.

Learn more about Dr. Rihal’s recent research activities.

Share
By Miriam Wuensch | Posted in Cardiovascular | Tagged , , , , | Leave a comment

Identification and treatment of eating disorders in the primary care setting

August 5th, 2010 - 2:49 pm

Dr. Leslie Sim discusses a clinical review that surveys recent literature related to the main eating disorders seen in primary care, including anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), night-eating syndrome (NES), and eating disorder not otherwise specified (EDNOS). The review, published in the August 2010 issue of Mayo Clinic Proceedings, details the signs and symptoms of each of these eating disorders, screening tests to detect them, and pharmacological and psychosocial approaches to their treatment.

ABSTRACT
Background: Eating disorders, which are associated with a host of adverse medical morbidities, negative psychological sequelae, and considerable reductions in quality of life, should be diagnosed and treated promptly. However, primary care physicians may find it uniquely challenging to detect eating disorders in their early stages, before obvious physical problems arise and while psychological symptoms are subtle. Although psychological symptoms may dominate the presentation, the physician is an integral member of the treatment team and is in a unique role to diagnose and treat eating disorders.

Methods: This clinical review surveys the eating disorders literature, identified by searching MEDLINE and PubMed for articles published from January 1, 1983, to September 30, 2009, using the following keywords: anorexia nervosa, bulimia nervosa, eating disorders, eating disorders NOS, binge eating, binge eating disorder, and night eating syndrome. This review also focuses on practical issues faced by primary care physicians in the management of these conditions and other issues central to the care of these complex patients with medical and psychiatric comorbid conditions.

Conclusions: Eating disorders are severe psychological illnesses associated with a host of adverse medical morbidities, negative psychological sequelae, and substantial reductions in quality of life. Given these consequences and the fact that health service utilization among people with eating disorders is relatively high, it is particularly important for physicians to adequately assess for these disorders. Although the eating disorders presented in this review vary widely in their demographic, weight, and symptom presentations, most benefit from a coordinated multidisciplinary effort, often involving specialized psychological treatment, medication management, and medical monitoring.

Share
By Carol Lammers | Posted in Pediatric, Psychiatry | Tagged , , , , | Comments (1)

REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century

July 29th, 2010 - 9:25 am

A study of 27 patients with histories of REM sleep behavioral disorder predating onset of clinical Parkinson’s disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA) by more than 15 years illustrates that the ά-synuclein pathogenic process may start decades before the first symptoms of PD, DLB, or MSA. This study was published on July 28, 2010 in Neurology.

ABSTRACT
Background: Idiopathic REM sleep behavior disorder (RBD) may be the initial manifestation of synucleinopathies (Parkinson disease [PD], multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]).

Methods: We used the Mayo medical records linkage system to identify cases presenting from 2002 to 2006 meeting the criteria of idiopathic RBD at onset, plus at least 15 years between RBD and development of other neurodegenerative symptoms. All patients underwent evaluations by specialists in sleep medicine to confirm RBD, and behavioral neurology or movement disorders to confirm the subsequent neurodegenerative syndrome.

Results: Clinical criteria were met by 27 patients who experienced isolated RBD for at least 15 years before evolving into PD, PD dementia (PDD), DLB, or MSA. The interval between RBD and subsequent neurologic syndrome ranged up to 50 years, with the median interval 25 years. At initial presentation, primary motor symptoms occurred in 13 patients: 9 with PD, 3 with PD and mild cognitive impairment (MCI), and 1 with PDD. Primary cognitive symptoms occurred in 13 patients: 10 with probable DLB and 3 with MCI. One patient presented with primary autonomic symptoms, diagnosed as MSA. At most recent follow-up, 63% of patients progressed to develop dementia (PDD or DLB). Concomitant autonomic dysfunction was confirmed in 74% of all patients.

Conclusions: These cases illustrate that the ά-synuclein pathogenic process may start decades before the first symptoms of PD, DLB, or MSA. A long-duration preclinical phase has important implications for epidemiologic studies and future interventions designed to slow or halt the neurodegenerative process.

Share
By Carol Lammers | Posted in Neurology | Tagged , , | Leave a comment

Stability of the diagnosis of mild cognitive impairment

July 12th, 2010 - 4:43 pm

Amnestic mild cognitive impairment (aMCI) is a subtype of MCI that has been associated with a likely progression to Alzheimer’s disease (AD). However, some subjects with MCI revert to “normal cognition,” and this raises the question of the stability of the diagnosis. A recent Mayo Clinic Study found that while the diagnosis of MCI was occasionally given to persons who subsequently were considered cognitively normal, such outcomes were uncommon.

Dr. Ronald Petersen presented these finding at the 2010 ICAD annual meeting.

ABSTRACT
Background: Amnestic mild cognitive impairment  is a subtype of MCI that has been associated with a likely progression to Alzheimer’s disease, and non-amnestic MCI (naMCI) likely represents the early stages of AD and non-AD dementias. However, some subjects with MCI revert to “normal cognition,” and this raises the question of the stability of the diagnosis.

Methods: The Mayo Clinic Study of Aging is a longitudinal population-based study of non-demented subjects ages 70-89 years. The subjects are evaluated every 15 months with a history from the subject and informant, neuropsychological tests covering four cognitive domains and a neurologic evaluation performed by a physician. A consensus conference is convened after each subject is evaluated, and the diagnosis of normal, aMCI, naMCI and dementia are made according to published criteria. A consensus diagnosis is obtained when two of the three evaluators agree with the diagnosis, and concordance is achieved when all three evaluators agree.

Results: For this study, 329 subjects with MCI at baseline were evaluated 15 and 30 months later. The overall incidence rate of developing dementia from MCI was 6.4% per year. For aMCI, the rate was 6.9%, and 5.2% for naMCI. In general, multi-domain aMCI had the highest rate of progression at 11.1% per year, according to consensus diagnoses. Using the concordant diagnoses, the overall rate of progression was 7.1% per year and 7.8% per year for aMCI and 5.5% per year for naMCI. The highest incidence rates were achieved for concordant diagnoses of multi-domain aMCI at 12.3% per year. The rates of reversion to normal for consensus MCI diagnoses was 8.8% per year, and for concordant diagnoses, 6.8% per year. The likelihood of remaining stable or progressing to dementia over three years of followup was quite high, 91.2% for consensus and 93.2% for concordant MCI diagnoses.

Conclusion: While the diagnosis of was MCI occasionally given to persons who subsequently were considered cognitively normal, such outcomes were uncommon. A diagnosis of MCI implies genuine cognitive impairment and represents a stable or progressive condition. Support for this study came from NIA: U01 AG006786 and P50 AG016574.

Share
By Carol Lammers | Posted in Neurology | Tagged , , , , | Comments (1)

Risk factors, prevention and noninvasive treatments for uterine fibroids

July 1st, 2010 - 9:45 am

Dr. Shannon Laughlin discusses her research on the non-invasive treatments for uterine fibroids.  Her research includes NIH funded Clinical trials.  

Clinical trial information
Mayo Clinic Related research
Treatment Information

Share
By Carol Lammers | Posted in Gynecology | Tagged , , , , , | Leave a comment

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147

June 22nd, 2010 - 3:38 pm

Dr. Steven Alberts discusses how the Mayo Clinic research team was surprised to find that a targeted therapy that provides benefit to patients with metastatic colon cancer failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone. The first public discussion of this Mayo Clinic led study and results was during the annual meeting of the American Society of Clinical Oncology (ASCO).


ABSTRACT
Background: FOLFOX is standard adjuvant therapy for stage III CC. Adding Cmab to FOLFOX benefits pts with metastatic CC WT KRAS tumors. N0147 assessed the potential benefit of Cmab added to FOLFOX.

Methods: 21-56 days following resection and informed consent, KRAS status was centrally determined. Pts with wtKRAS CC were randomized to 12 biweekly cycles of oxaliplatin 85 mg/m2 d1, with leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus IV, then 46-hr IV 5FU 2,400 mg/m2 on d1-2 (mFOLFOX6), without (arm A) or with Cmab (arm D) 250 mg/m2 d1&8, with Cmab at 400 mg/m2, cycle 1, d1. Primary endpoint was 3-yr disease free survival (DFS). Secondary endpoints included overall survival (OS) and toxicity. Planned accrual of 2,070 wtKRAS pts provided 90% power to detect hazard ratio (HR) of 1.33 with 2-sided α=0.05; with interim analyses after 25%, 50%, and 75% of planned events.

Results: 1,760 wtKRAS pts (Arm A-858, Arm D-902) were enrolled at the time of closure; median follow-up on 1,624 pts is 15.9 months. Trial closed to accrual when preplanned interim analysis after 50% of planned events demonstrated no benefit to addition of Cmab. 3-yr DFS favored FOLFOX alone (HR 1.18, 95% CI 0.92-1.52; p=0.33). No benefit of Cmab was observed in any subgroups assessed. Any grade ≥ 3 AE, diarrhea, and failure to complete 12 cycles was significantly increased in arm D. Increased toxicity and greater differences in all outcomes were observed in pts aged ≥ 70 (Table).

Conclusions: In this randomized phase III trial the addition of Cmab to mFOLFOX6 was of no benefit for pts with resected stage III wtKRAS CC.
Supported by NIH Grant CA25224, Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer.

AUTHORS
S. R. Alberts, D. J. Sargent, T. C. Smyrk, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. N. Thibodeau, S. Nair; Mayo Clinic, Rochester, MN; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Vanderbilt University Medical Center, Nashville, TN; University of North Carolina at Chapel Hill, Chapel Hill, NC; British Columbia Cancer Agency, Vancouver, BC, Canada; University of Texas Health Science Center at San Antonio, San Antonio, TX; North Central Cancer Treatment Group, Allentown, PA

Share
By Carol Lammers | Posted in Cancer | Tagged , , , , , , | Comments (2)